SHENYANG, China, Aug. 20, 2011 /PRNewswire-Asia-FirstCall/ —
3SBio Inc. (NASDAQ:
SSRX) (“3SBio” or “Company”), a leading China-based
biotechnology company focused on researching, developing,
manufacturing and marketing biopharmaceutical products, today
announced that the annual general meeting of shareholders of 3SBio
Inc. will be held on September 20, 2011 at 10:00 a.m.,
Shenyang time, at our executive office, 15/A-D, Huaxin
International Tower, No. 219, Qingnian Ave., Shenhe District,
Shenyang 110016, People’s Republic of China. The shareholder record
date is August 15, 2011.
3SBio has filed its annual report on Form 20-F with the audited
financial statements for the fiscal year ended December 31, 20010,
with the U.S. Securities and Exchange Commission (the “SEC”).
3SBio’s annual report on Form 20-F can be accessed on the Investors
section of the Company’s website at http://www.3SBio.com, as well as
on the SEC’s website at http://www.sec.gov. The materials
related to the annual general meeting, including the notice of
meeting, the proxy statement, and the voting card may also be
accessed and downloaded at the Investors section of the Company
website. Shareholders may request a hard copy of the
above documents free of charge by contacting
ir@3SBio.com.
About 3SBio Inc.
3SBio is a leading, fully integrated, profitable biotechnology
company focused on researching, developing, manufacturing and
marketing biopharmaceutical products primarily in China. Its
focus is on addressing large markets with significant unmet medical
needs in nephrology, oncology, supportive cancer care, inflammation
and infectious diseases. With headquarters and GMP-certified
manufacturing facilities in Shenyang, PRC, 3SBio employs over 700
peop
‘/>”/>
